PROGYNY INC
PGNYNASDAQTrading Snapshot
- Day Range
- $24.34 – $24.70
- 52-Week Range
- $16.10 – $33.07
- Volume
- $2.59B
- Avg Volume
- $3.22B
- Shares Outstanding
- 78.3M
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.29B
- Last Q Revenue
- $351M
- P/E Ratio
- 26.3
- P/S Ratio
- 1.5x
- EPS (TTM)
- $1.01
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −6.3%
Why Investors Own PGNY
- ✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROGYNY INC
PGNY
StockOtter · stockotter.spaceAbout PROGYNY INC
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
PGNY vs. CRL: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportu
Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% rev
Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know
The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at
Hsbc Holdings PLC Makes New $760,000 Investment in Progyny, Inc. $PGNY
Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquire
23,600 Shares in Progyny, Inc. $PGNY Bought by Canada Pension Plan Investment Board
Canada Pension Plan Investment Board acquired a new stake in Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 23